Addressing a clinical challenge: guidelines for the diagnosis and treatment of leishmaniasis by Naomi E. Aronson
COMMENTARY Open Access
Addressing a clinical challenge: guidelines




Leishmaniasis is a chronic intracellular parasitic infection that travelers, immigrants, deployed military personnel, and
refugees from endemic global areas acquire from the bite of infected sand flies and carry with them, including to
non-endemic countries where leishmaniasis may be an unfamiliar illness to medical providers. This commentary
discusses the first clinical practice guidelines produced by the Infectious Diseases Society of America and American
Society of Tropical Medicine and Hygiene for the diagnosis and management of leishmaniasis, targeted for
clinicians in North America.
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Background
Leishmaniasis, caused by various Leishmania parasites
and transmitted by the bite of an infected sand fly vector,
is on the rise [1]. An immunologically unprotected host
who travels to any of the 88 countries with areas of en-
demic leishmaniasis is at risk of acquiring infection.
Whether the inciting event be population displacement
due to conflict or food insecurity, refugee relocation, eco-
tourism, urbanization, or northward extension of the sand
fly vector with global warming trends, the end result is
that more patients with cases of leishmaniasis will present
to healthcare systems in non-endemic Europe and North
America. Some countries (e.g., India, Bangladesh, Nepal)
are working toward eliminating visceral leishmaniasis
(VL); however, VL epidemics occur in Sudan and South
Sudan, and there are increased rates of VL cases in Brazil
as a result of populations moving from rural to densely
populated peri-urban regions. Recent epidemics of cutane-
ous leishmaniasis (CL) have been associated with an earth-
quake in Bam, Islamic Republic of Iran; with refugees
and displaced persons in Kabul, Afghanistan; with the
US military operations in Operation Iraqi Freedom
2003–2005; and as a consequence of the conflict in Syria.
The United Nations High Commissioner for Refugees
reported that 65 million persons were displaced in 2015
and that three countries provided one half of the worlds’
refugees: Syria, Afghanistan, and Somalia [2]. In two of
these countries, Syria and Afghanistan, leishmaniasis is
endemic. The visible signs of CL (chronic skin sores often
on exposed parts of the body) broadcast an obvious indi-
cation of emerging infection in unprotected populations.
While the Syrian Ministry of Health reported a twofold in-
crease in CL cases in 2013, some feel the number of CL
cases could exceed 100,000 per year [3]. In a GeoSentinel
surveillance study, 32% of adult Syrian refugees evaluated
for migration-related illness had CL [4]. Increased CL
rates were also reported in the neighboring countries of
Jordan [5], Lebanon [6, 7], and Turkey [8, 9], primarily
among Syrian refugee populations. Poor living conditions,
disrupted healthcare infrastructure, vector control pro-
grams, inadequate sanitation, and mass migration from
non-endemic regions of Syria through endemic areas all
likely contribute to an increased disease burden of leish-
maniasis in Syrian refugees.
An additional contributor to the rise of VL is decreased
host susceptibility. Globally, this is most commonly caused
by malnutrition, but in high-resourced countries this can
also be caused by immunosuppression. Causative factors
for the latter include HIV–Leishmania co-infection, ini-
tially recognized in Mediterranean intravenous drug users
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but now seen worldwide, and risks associated with biologic
immunomodulating drugs, including post transplantation,
and with the burgeoning use of tumor necrosis factor-
alpha inhibitors [10, 11].
Discussion
In 2007, the World Health Assembly passed a resolution
on the control of leishmaniasis, raising awareness of
these infections [12]. Subsequently, several major clinical
guidelines have been published, but they were not tar-
geted toward clinical management in North America
[13]. In the USA, there is a dichotomous dilemma with
the diagnosis and care of patients with leishmaniasis.
Healthcare is well resourced, but leishmaniasis is not en-
demic and most providers may not recognize the typical
signs and symptoms. Aside from histopathology, diag-
nostic testing is relegated to a few reference laboratories
only. Most drugs used globally to treat leishmaniasis are
not approved by the Food and Drug Administration for
use in the USA and may not be easily available. In light
of these challenges, detailed clinical practice guidelines
for the diagnosis and management of leishmaniasis in
North America were recently published [14, 15] after an
inaugural collaboration between the Infectious Diseases
Society of America (IDSA) and the American Society of
Tropical Medicine and Hygiene (ASTMH).
The IDSA-ASTMH leishmaniasis clinical practice guide-
lines were structured by including questions that com-
monly arise in clinical practice. They provide practical
tables, maps of endemic areas, clinical photographs, and
contact details for reference diagnostic laboratories. These
guidelines are detailed; they are organized into nine diag-
nostic questions (22 recommendations) and 26 treatment
questions (57 recommendations) covering CL, mucosal
leishmaniasis (ML), VL, and leishmaniasis management in
the immunocompromised host and in special populations
(young children, elderly persons, women who are pregnant
or lactating, and persons with medical comorbidities). Only
the executive summary is published in paper format, but
each question has an associated evidence summary avail-
able online. The guidelines are extensively referenced
(>500 references) and a supplemental appendix has a
searchable document of controlled CL treatment trials,
transparently allowing a provider to assess the quality of
evidence, and allowing them to search by country of acqui-
sition, Leishmania species, and type/route of treatment.
Many of the guideline recommendations derive from ob-
servational trials and case reports, or consist of expert
opinion. Recommendations are given based on a determin-
ation of the strength of the recommendation (strong or
weak) and the quality of evidence (high, moderate,
low, very low). In the guidelines, 14% of the diagnos-
tic recommendations and 16% of the therapeutic rec-
ommendations were rated as weak; with regards the
quality of evidence, diagnostic (32% moderate, 48% low,
19% very low) and therapeutic (4% high, 20% moderate,
49% low, and 27% very low) recommendations were
skewed to lower-quality studies.
In the context of a majority of low/very low quality of
evidence, applying GRADE (grading of recommenda-
tions, assessment, development, and evidence) method-
ology is challenging. Early on, the committee decided to
address questions for clinicians, whether or not the pub-
lished evidence was adequate. The guidelines took in ex-
cess of 5 years to complete and are lengthy as well as
complex. For the North American audience, new areas
of focus include managing immunocompromised hosts
(not just HIV) and special populations, and a discussion
of the new drug, miltefosine, and its current role in
treatment. Local therapies are reviewed for treating un-
complicated leishmaniasis, such as Old World CL; these
approaches have been underutilized in the USA. Some
of the more controversial recommendations among the
group included whether to refer patients with Viannia
subgenus infection for expert otolaryngological examin-
ation regardless of symptoms (the chosen recommendation
was that these patients should be referred). Another con-
troversial topic was whether determining the Leishmania
species responsible for the infection (requiring culture or
reference laboratory support) is informative enough to
make it worthwhile in most cases (again, the answer was
yes). The use of serology alone (rK39) for the diagnosis of
VL was discouraged, with the recommendations advocat-
ing for parasitic confirmation. The sole recommendation
for which consensus was not reached was whether New
World CL north of Costa Rica could be managed by
observation without intervention—if healing on its
own—because it is geographically thought to have less
risk of metastasizing to cause ML; one member with
a great deal of ML experience felt that all should re-
ceive treatment.
Preparing these leishmaniasis guidelines often led to
more questions than answers. One area ripe for add-
itional research is the management of leishmaniasis in
the non-HIV immunocompromised host (e.g., post
transplant or being treated with biologic immunomodu-
lating drugs). In general, this neglected tropical disease
requires fully powered sample sizes in well-done com-
parative clinical trials with standardized outcome mea-
sures to develop a stronger evidence base. This will
likely require the collaboration of consortia across re-
gions to refine the best treatment approaches. Until this
evidence is available, the guidelines generally define sim-
ple and complicated CL as the initial decision node for
local versus systemic treatment, but emphasize that
treatment choice should be individualized; there is no
universally applicable treatment dose, route of adminis-
tration, drug, or duration of therapy.
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Conclusions
The IDSA-ASTMH clinical practice guidelines provide a
sensible current approach for clinicians evaluating and
treating patients with leishmaniasis. We aimed to give
clear recommendations from evidence that was often in-
adequate, but drawing upon our collective clinical ex-
pertise in managing leishmaniasis. More leishmaniasis
cases are now seen in adventurous travelers, immigrants,
refugees, and military personnel. These guidelines serve
as a definitive reference to assist with the management
of this clinically challenging infection. Lastly, the notable
absence of an effective vaccine for leishmaniasis or
prophylactic treatment highlights that prevention is es-
sential to stopping the global rise of leishmaniasis.
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